STSA News and Press, Satsuma Pharmaceuticals Inc. From 03/03/22

SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

Satsuma Pharmaceuticals (NASDAQ:STSA): Q3 GAAP EPS of -$0.42 beats by $0.09. Cash, cash equivalents and marketable securities of $110.15M. Press Release For further details see: Satsuma Pharmaceuticals EPS beats by $0.09

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of September 30, 2021 provides runway into second half of 2023 – ...

Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors PR Newswire DELRAY BEACH, Fla. , Nov. 9, 2021 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to...

Today, we take our first look at a small biopharma company called Satsuma Pharmaceuticals. The company is targeting migraines with a unique delivery approach. A full investment analysis follows in the paragraphs below. For further details see: Satsuma Pharmaceuticals: Si...

Gainers: Greenidge Generation Holdings (NASDAQ:GREE) +9%. Aura Biosciences (AURA) +6%. Satsuma Pharmaceuticals (NASDAQ:STSA) +5%. SkyWest (NASDAQ:SKYW) +2%. Gambling.com Group (NASDAQ:GAMB) +2%. Losers: HCW Biologics (NASDAQ:HCWB) -7%. Viant Technology (NASDAQ:DSP) -5%. Pop Culture ...

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...